DOCSLIB.ORG

Primary Malignant Teratoma with a Primitive Neuroectodermal Tumor Component in Thyroid Gland : a Case Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Primary Malignant Teratoma with a Primitive Neuroectodermal Tumor Component in Thyroid Gland : a Case Report J Korean Med Sci 2007; 22: 568-71 Copyright � The Korean Academy ISSN 1011-8934 of Medical Sciences Primary Malignant Teratoma with a Primitive Neuroectodermal Tumor Component in Thyroid Gland : A Case Report Teratomas comprise the most common extragonadal germ cell tumors in childhood. Eunyoung Kim, Tae Seok Bae, Most teratomas involving the thyroid are benign and occur in children. However, Youngmee Kwon, Tae Hyun Kim, the adult cases reported are mostly malignant and commonly arise in the thyroid. Ki-Wook Chung, Sun Wook Kim, We report a case of a 31-yr-old female with a huge neck mass. Pathologic examina- Jungsil Ro, Eun Sook Lee tion revealed it to be malignant teratoma composed of primitive neuroepithelial tis- Research Institute and Hospital, National Cancer sue with primitive neural tubes and loose myxoid to fibrous immature mesenchymal Center, Goyang, Korea stroma. The patient underwent extensive evaluation of the thyroid gland with com- puted tomography (CT) scan and positron emission tomography (PET) scan, which Received : 29 September 2005 revealed no evidence of metastatic disease. She underwent total thyroidectomy Accepted : 9 March 2006 with bilateral modified radical neck dissection, intensive chemotherapy and radio- therapy. At 22-months of follow-up, the patient has remained euthyroid and showed no evidence of recurrence. This is the first case, to our knowledge, of malignant Address for correspondence Eun Sook Lee, M.D. thyroid teratoma with a exuberant primitive neuroectodermal tumor component in Center for Breast Cancer, National Cancer Center, Korea. 809 Madu-1-dong, Ilsan-gu, Goyang 411-769, Korea Tel : +82.31-920-1633, Fax : +82.31-920-1759 Key Words : Malignant Teratoma; Thyroid Neoplasm; Thyroid Disease E-mail : [email protected] INTRODUCTION erogeneous enhancing mass arising in the right lobe of thy- roid gland (Fig. 1). It was invading beyond the thyroid gland Teratomas comprise the most common extragonadal germ and extended down to the anterior mediastinum. The trachea cell tumors in childhood (1). Teratomas of the neck in adults and right sternocleidomastoid muscle were deviated to the are extremely rare. The tumors of the head and neck account left. The supraclavicular, highest mediastinal, and bilateral for 5% of all benign and malignant germ cell tumors and for prevascular lymph nodes were all enlarged. The largest lymph 6% of all teratomas, where the most common sites of involve- node was over 2.5 cm at the levels II and III. ment are the soft tissue of the neck, thyroid, superficial facial The F-18-FDG positron emission tomography (PET) scan structures, oral cavity, nasopharynx, and orbit (1, 2). Most showed a huge hypermetabolic mass in the right thyroid gland teratomas involving the thyroid are benign and occur in chil- with multiple hypermetabolic lesions in the neck and in the dren. We report a case of primary malignant thyroid terato- prevascular area of mediastinum. Fine needle aspiration slides ma in a 31-yr-old female. To our knowledge, this is the first revealed diffusely scattered oval to spindle shaped atypical case of malignant teratoma with a primitive neuroectoder- cells with rare eosinophilic amorphous material suggesting mal tumor component in the thyroid in Korea. poorly differentiated carcinoma possibly consistent with me- dullary carcinoma. She underwent total thyroidectomy with bilateral modified radical neck dissection. The tumor was CASE REPORT penetrating the thyroid capsule and was invading the adja- cent tissue involving the right recurrent laryngeal nerve. The A 31-yr-old woman presented to our clinic with a two- upper portion of the sternum was cut to dissect the inferior month history of a fast growing non-tender mass in the neck. portion of right thyroid. The lymph nodes along the chain No pertinent past medical illness or family history was pre- were removed after the sheaths of the common carotid, and sent. On physical examination, a large hard and fixed mass internal jugular vein were opened. The postoperative period was palpated in the central neck, mostly occupying the thy- was uneventful except transient hypocalcemia. On the third roid gland. The laboratory findings were unremarkable, and day of operation, the total serum calcium level was 6.7 mg/ her thyroid function was normal. The computed tomogra- dL with a ionized calcium level of 0.88 mM/L. Calcium was phy scanning of the neck showed a 7.0×5.5 cm solid het- replaced by oral medication. 568 Malignant Thyroid Teratoma 569 On gross examination, the mass was occupying most of the mainly composed of primitive neuroepithelial tissue with right lobe of thyroid gland with a ill-defined border, measur- primitive neural tubes and loose myxoid to fibrous immature ing 7.5×5.0×4.7 cm. The cut surface was grayish white, mesenchymal stroma (Fig. 3). The normal thyroid follicles hemorrhagic, and necrotic with focal cystic changes. Many were intermingled or adjacent to the tumor. The tumor cells lymph nodes were grossly involved by the tumor (Fig. 2). were pleomorphic and partly necrotic with hyperchromatism The microscopic examination showed that the tumor was and frequent mitotic figures (4-6/10 high power fields). A Fig. 1. Computed tomography (CT) scan of malignant teratoma. Fig. 2. Gross finding of malignant teratoma. The mass is mainly A 7.0×5.5 cm mass is observed within the right anterior neck. located in the right lobe of thyroid with extrathyroidal extension The trachea and right sternocleidomastoid muscle are deviated and multiple lymph node involvement. to the left. Fig. 3. Microscopic findings of malignant teratoma. The tumor is Fig. 4. Microscopic findings. Mature cartilage is also noted within mainly composed of primitive neuroepithelial cells and neural tu- the primitive neuroepithelial tissue (H&E stain, ×100). bules (H&E stain, ×100). 570 E. Kim, T.S. Bae, Y. Kwon, et al. multitude of small cystic spaces was lined by mature squa- phamide and actinomycin-D (2, 6). mous or glandular epithelium. Islands of mature cartilage Chen et al. reported a 32-yr-old woman with malignant were noted within the primitive neuroepithelial tissue (Fig. thyroid teratoma who underwent a simple lobectomy of the 4). Metastases were present in 25 of total 58 lymph nodes, thyroid (8). She received chemotherapy of BEP and was still where metastatic components were only composed of a prim- alive without evidence of disease after 6.7 yr. No further local itive neuroepithelial component. The tumor cells were posi- radiotherapy or operation was arranged. tive for synaptophysin, focally positive for cytokeratin, neu- Djalilian, et al. reported a 33-yr-old woman with malignant rofilament, desmin, and CD99 on immunohistochemical thyroid teratoma who underwent 5 cycles of chemotherapy staining. The primitive neuroepithelial component comprised with vinblastin, ifosfamide, and cisplatin (1). After 3 further more than 4 in low power magnification fields (×4 objec- cycles of carboplatin and etoposide, the patient underwent tive with a ×10 ocular, using bvx.), which thus was catego- autologous bone marrow stem cell transplant. She did well rized as malignant teratoma according to the Thompson et with evidence of stable disease in the lungs at 21 months from al.’s criteria (3). the diagnosis but died of metastatic teratoma. Recently, high- After she recovered from the surgery, she was placed on dose chemotherapy in combination with autologous stem an intensive chemotherapy according to the National Can- cell transplant has been found to be effective in prolonging cer Institute protocol reported by Grier et al. (4). She received the survival in some patients with gonadal germ cell tumors 14 cycles of chemotherapy consisting of VAC (vincristine 2 (10, 11). mg, doxorubicin 75 mg/m2, cyclophosphamide 1,200 mg/ Jayaram et al. treated a malignant teratoma of the thyroid m2, every 3 weeks), alternate with IE (ifosfamide 1,800 mg/ with predominantly neuroepithelial differentiation with sur- m2 with mesna, and etoposide 100 mg/m2 for five days by gery alone (7). She died after 15 months with metastases to continuous infusion). liver, vertebra, paraaortic and paracaval lymph nodes. After the completion of the 10th cycle of chemotherapy, Craver et al. reported a 15-yr-old black girl with a malig- she received external beam radiation therapy (EBRT) with a nant thyroid teratoma with exuberant primitive neuroecto- total dose of 55.8 Gy, 5 days/week. The treated volume in- dermal tumor components. There were bilateral nodal involve- cluded the thyroid bed, cervical lymph nodes, and upper ment and mediastinal extension (6). She was treated with an mediastinum. Upon completion of radiation therapy, she aggressive combination chemotherapy of BEP and radiation. received further chemotherapy. Dactinomycin at 1.25 mg/ Further chemotherapy included vincristin, actinomycin-D, m2 replaced doxorubicin. The patient completed total 17 and cyclophosphamide alternating with ifosfamide and eto- cycles of chemotherapy. Dose reductions along with granu- poside for six cycles. These agents were included to treat the locyte colony-stimulating factor and erythropoietin supports sarcomatous component. Presently there is no residual dis- were done. ease 16 months after the diagnosis. She has been remains free of disease for 22 months after Kushner et al. treated 36 patients with poor-risk primi- the diagnosis. tive neuroectodermal tumor (12). The P6 protocol consists of high-dose cyclophosphamide, doxorubicin, and vincristine. The protocol achieved excellent pathological or clinical res- DISCUSSION ponses in 34 patients and partial responses in two patients. All six patients with metastatic disease limited to lungs Malignant teratoma of the thyroid in adult was first report- achieved a complete response and did not relapse for the fol- ed by Lurje in 1908, who described a case of a 53-yr-old wo- low-up period of 7 to 36 months. man (5). By 1999, nineteen cases of malignant teratoma of Primary thyroid malignant teratoma is rare.
Load more

Recommended publications
  • Endo4 PRINT.Indb
    Contents 1 Tumours of the pituitary gland 11 Spindle epithelial tumour with thymus-like differentiation 123 WHO classifi cation of tumours of the pituitary 12 Intrathyroid thymic carcinoma 125 Introduction 13 Paraganglioma and mesenchymal / stromal tumours 127 Pituitary adenoma 14 Paraganglioma 127 Somatotroph adenoma 19 Peripheral nerve sheath tumours 128 Lactotroph adenoma 24 Benign vascular tumours 129 Thyrotroph adenoma 28 Angiosarcoma 129 Corticotroph adenoma 30 Smooth muscle tumours 132 Gonadotroph adenoma 34 Solitary fi brous tumour 133 Null cell adenoma 37 Haematolymphoid tumours 135 Plurihormonal and double adenomas 39 Langerhans cell histiocytosis 135 Pituitary carcinoma 41 Rosai–Dorfman disease 136 Pituitary blastoma 45 Follicular dendritic cell sarcoma 136 Craniopharyngioma 46 Primary thyroid lymphoma 137 Neuronal and paraneuronal tumours 48 Germ cell tumours 139 Gangliocytoma and mixed gangliocytoma–adenoma 48 Secondary tumours 142 Neurocytoma 49 Paraganglioma 50 3 Tumours of the parathyroid glands 145 Neuroblastoma 51 WHO classifi cation of tumours of the parathyroid glands 146 Tumours of the posterior pituitary 52 TNM staging of tumours of the parathyroid glands 146 Mesenchymal and stromal tumours 55 Parathyroid carcinoma 147 Meningioma 55 Parathyroid adenoma 153 Schwannoma 56 Secondary, mesenchymal and other tumours 159 Chordoma 57 Haemangiopericytoma / Solitary fi brous tumour 58 4 Tumours of the adrenal cortex 161 Haematolymphoid tumours 60 WHO classifi cation of tumours of the adrenal cortex 162 Germ cell tumours 61 TNM classifi
    [Show full text]
  • Endocrine Pathology (537-577)
    LABORATORY INVESTIGATION THE BASIC AND TRANSLATIONAL PATHOLOGY RESEARCH JOURNAL LI VOLUME 99 | SUPPLEMENT 1 | MARCH 2019 2019 ABSTRACTS ENDOCRINE PATHOLOGY (537-577) MARCH 16-21, 2019 PLATF OR M & 2 01 9 ABSTRACTS P OSTER PRESENTATI ONS EDUCATI ON C O M MITTEE Jason L. Hornick , C h air Ja mes R. Cook R h o n d a K. Y a nti s s, Chair, Abstract Revie w Board S ar a h M. Dr y and Assign ment Co m mittee Willi a m C. F a q ui n Laura W. La mps , Chair, C ME Subco m mittee C ar ol F. F ar v er St e v e n D. Billi n g s , Interactive Microscopy Subco m mittee Y uri F e d ori w Shree G. Shar ma , Infor matics Subco m mittee Meera R. Ha meed R aj a R. S e et h al a , Short Course Coordinator Mi c h ell e S. Hir s c h Il a n W ei nr e b , Subco m mittee for Unique Live Course Offerings Laksh mi Priya Kunju D a vi d B. K a mi n s k y ( Ex- Of ici o) A n n a M ari e M ulli g a n Aleodor ( Doru) Andea Ri s h P ai Zubair Baloch Vi nita Parkas h Olca Bast urk A nil P ar w a ni Gregory R. Bean , Pat h ol o gist-i n- Trai ni n g D e e p a P atil D a ni el J.
    [Show full text]
  • Endocrine Surgery Goals and Objectives
    Lenox Hill Hospital Department of Surgery Endocrine Surgery Goals and Objectives Medical Knowledge and Patient Care: Residents must demonstrate knowledge and application of the pathophysiology and epidemiology of the diseases listed below for this rotation, with the pertinent clinical and laboratory findings, differential diagnosis and therapeutic options including preventive measures, and procedural knowledge. They must show that they are able to gather accurate and relevant information using medical interviewing, physical examination, appropriate diagnostic workup, and use of information technology. They must be able to synthesize and apply information in the clinical setting to make informed recommendations about preventive, diagnostic and therapeutic options, based on clinical judgement, scientific evidence, and patient preferences. They should be able to prescribe, perform, and interpret surgical procedures listed below for this rotation. All Residents are expected to understand: 1. Normal physiology and anatomy of the thyroid glands. 2. Normal physiology and anatomy of the parathyroid glands. 3. Normal physiology and anatomy of the adrenal glands 4. Normal physiology of the pancreatic neuroendocrine cells. 5. Normal physiology of the pituitary gland. Disease-Based Learning Objectives: Hyperfunctioning Thyroid and Hypothyroid State: 1. Physiology of Grave’s disease and toxic goiter. 2. Management of a patient in hyperthyroid storm. 3. Medical and surgical treatment options for hyperthyroidism. 4. Physiology of Hashimoto’s thyroiditis and hypothyroidism. Thyroid Neoplasm: 1. Workup of a cold thyroid nodule. 2. Surgical management of papillary, follicular, medullary, and anaplastic thyroid carcinoma. 3. Adjuvant therapy for thyroid neoplasms. 4. Postoperative medical management and long-term follow-up of thyroid cancer. Hyperparathyroidism: 1. Diagnosis and work-up of hypercalcemia and primary, secondary, and tertiary hyperparathyroidism.
    [Show full text]
  • Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: an Overview Comparing Pediatric and Adult Populations
    cancers Review Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations 1, 2, 2 3 Aline Rangel-Pozzo y, Luiza Sisdelli y, Maria Isabel V. Cordioli , Fernanda Vaisman , Paola Caria 4,*, Sabine Mai 1,* and Janete M. Cerutti 2 1 Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada; [email protected] 2 Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de São Paulo/EPM, São Paulo, SP 04039-032, Brazil; [email protected] (L.S.); [email protected] (M.I.V.C.); [email protected] (J.M.C.) 3 Instituto Nacional do Câncer, Rio de Janeiro, RJ 22451-000, Brazil; [email protected] 4 Department of Biomedical Sciences, University of Cagliari, 09042 Cagliari, Italy * Correspondence: [email protected] (P.C.); [email protected] (S.M.); Tel.: +1-204-787-2135 (S.M.) These authors contributed equally to this paper. y Received: 29 September 2020; Accepted: 26 October 2020; Published: 27 October 2020 Simple Summary: Papillary thyroid carcinoma (PTC) represents 80–90% of all differentiated thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence clinical and biological behavior in both children and adults. In this review, we focus on the comparison between pediatric and adult PTC, highlighting genetic alterations, telomere-related genomic instability and changes in nuclear organization as novel biomarkers for thyroid cancers. Abstract: Thyroid cancer is a rare malignancy in the pediatric population that is highly associated with disease aggressiveness and advanced disease stages when compared to adult population.
    [Show full text]
  • Validation of Algorithms to Identify Pancreatic Cancer and Thyroid Neoplasms from Health Insurance Claims Data in a 10-Year Foll
    Validation of Algorithms to Identify Pancreatic Cancer and Thyroid Neoplasms From Health Insurance Claims Data in a 10-Year Follow-Up Study Caihua Liang, MD, PhD1*; Monica L Bertoia, MPH, PhD1; C Robin Clifford, MS1; Yan Ding, MSc1; Qing Qiao, MD, PhD2; Joshua J Gagne, PharmD, ScD1,3; David D Dore, PharmD, PhD1 1Optum Epidemiology, Boston, MA/Ann Arbor, MI, USA; 2Global Medical Affair AstraZeneca, Gothenburg, Sweden; 3Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA. *Corresponding author: [email protected]. This study was funded through a research contract between Optum Epidemiology and AstraZeneca. Background Methods (cont.) Identification of cancer events in health insurance claims data can be Figure 1. Pancreatic cancer and thyroid neoplasm relaxed and restricted challenging and subject to misclassification. Given the low incidence of algorithms certain cancers, robust performance evaluation requires a large sample size PANCREATIC CANCER THYROID NEOPLASMS with long-term follow-up. ICD-9 Codes ICD-9 Codes (Malignant neoplasm of …) 193 Malignant neoplasm of thyroid gland 157.X … pancreas 226 Benign neoplasm of thyroid gland Objective 157.0 … head of pancreas 157.1 … body of pancreas Thyroid Cancer Benign Thyroid Neoplasm To validate algorithms for potential incident pancreatic cancer and thyroid 157.2 … tail of pancreas neoplasms in a 10-year follow-up study using a health insurance claims 157.3 … pancreatic duct Restricted Algorithm: Restricted Algorithm: 157.4 … islets of Langerhans a+b+c a+b+c database. 157.8 … other specified sites of Relaxed Algorithm: Relaxed Algorithm: pancreas a+b or a+c a+b or a+c 157.9 … pancreas, part unspecified Data Source a.
    [Show full text]
  • Significance of RAS Mutations in Thyroid Benign Nodules and Non
    cancers Review Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer Vincenzo Marotta 1 , Maurizio Bifulco 2 and Mario Vitale 3,* 1 UOC Clinica Endocrinologica e Diabetologica, AOU S. Giovanni di Dio e Ruggi D’Aragona, 84131 Salerno, Italy; [email protected] 2 Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80100 Naples, Italy; [email protected] 3 Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Baronissi, Italy * Correspondence: [email protected]; Tel.: +39-089-672-753 Simple Summary: Only about 4% of thyroid nodules are carcinomas and require surgery. Fine- needle aspiration cytology is the most accurate tool to distinguish benign from malignant thyroid nodules, however it yields an indeterminate result in about 30% of the cases, posing diagnostic and prognostic dilemmas. Testing for genetic mutations, including those of RAS, has been proposed for indeterminate cytology to solve these dilemmas and support the clinician decision making process. A passionate debate is ongoing on the biological and clinical significance of RAS mutations, calling into question the utility of RAS as tumor marker. Recently, the description of a new entity of non- invasive follicular thyroid neoplasm and the accurate review of more recent analyses demonstrate that RAS mutations have limited utility in both the diagnostic and prognostic setting of thyroid nodular disease. Citation: Marotta, V.; Bifulco, M.; Abstract: Thyroid nodules are detected in up to 60% of people by ultrasound examination. Most Vitale, M. Significance of RAS of them are benign nodules requiring only follow up, while about 4% are carcinomas and require Mutations in Thyroid Benign surgery.
    [Show full text]
  • 2018 Updates for Neoplasms of the Thyroid
    12/11/2018 2018 Updates for Neoplasms of the Thyroid 1 2 0 1 8 - 2019 FCDS WEBCAST SERIES 1 2 / 1 3 / 2 0 1 8 S T E V E N P E A C E , C T R CDC & Florida DOH Attribution 2 “Funding for this conference was made possible (in part) by the Centers for Disease Control and Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the US Government.” FCDS would also like to acknowledge the Florida Department of Health for its support of the Florida Cancer Data System, including the development, printing and distribution of materials for the 2018 FCDS Annual Conference and the 2018-2019 FCDS Webcast Series under state contract CODJU. The findings and conclusions in this series are those of the author(s) and do not necessarily represent the official position of the Florida Department of Health. 1 12/11/2018 FLccSC LMS – CEU Quiz –FCDS IDEA 3 2017 - Florida Changed How FCDS Awards CEUs for FCDS Webcasts Attendees must take and pass a 3-5 question CEU Quiz to get CEUs CEU Awards are Restricted to Attendees with a FLccSC LMS Account The CEU Quiz will be posted to FLccSC 1-2 hours after the webcast ends Only registered FLccSC Users will be given access to the CEU Quiz Florida attendees must have a Florida FLccSC Account to take the Quiz South Carolina attendees must have a South Carolina FLccSC Account
    [Show full text]
  • A Clinical Study on Malignant Neoplastic Thyroid Swellings
    Jebmh.com Original Research Article A Clinical Study on Malignant Neoplastic Thyroid Swellings Sumanth Mandava1, Tarun Chowdary Gogineni2, Vasu Reddy Challa3, Karthik Santosh Appaji4 Sriphani Reddy Puvvala5, T. Jaya Chandra6 1, 2, 3, 5 Department of Surgical Oncology, GSL Medical College, Rajahmundry, Andhra Pradesh, India. 4Department of General Surgery, GSL Medical College, Andhra Pradesh, India. 6Scientist in Charge, Central Research Laboratory, GSL Medical College, Andhra Pradesh, India. ABSTRACT BACKGROUND More thyroid malignancy cases occur in women. FNAC (Fine Needle Aspiration Corresponding Author: Cytology) and histopathology play a key role in resolving this diagnostic challenge. Dr. Vasu Reddy Challa, A study was conducted to correlate the age, gender parameters with the clinical Associate Professor, Department of Surgical Oncology, findings in thyroid malignancies by considering the histopathological examination GSL Medical College, Rajahmundry, (HPE) as the gold standard. Andhra Pradesh, India. E-mail: METHODS [email protected] It was a prospective study conducted in the department of Surgical Oncology, GSL Medical College, Rajahmundry, Malignant thyroid neoplasm individuals of any age, DOI: 10.18410/jebmh/2020/599 either gender who were fit thyroidectomy were included in the study. FNAC of the thyroid gland and lymph nodes was done. Data was analyzed using SPSS 21.0. Chi How to Cite This Article: square test was used to find the statistical significance. P > 0.05 was considered to Mandava S, Gogineni TC, Challa VR, et al. A clinical study on malignant neoplastic be statistically significant. thyroid swelling. J Evid Based Med Healthc 2020; 7(49), 2928-2932. DOI: RESULTS 10.18410/jebmh/2020/599 In this study, 52 HPE proven cases were studied, female male ratio was 5.5.
    [Show full text]
  • Spectrum of Malignancy and Premalignancy in Carney Syndrome
    American Journal of Medical Genetics 73:369–377 (1997) Spectrum of Malignancy and Premalignancy in Carney Syndrome Ngozi A. Nwokoro,1,2* Mary T. Korytkowski,3 Suzanne Rose,3 Michael B. Gorin,4 Mona Penles Stadler,2 Selma F. Witchel,5 and John J. Mulvihill2 1Department of Oral and Maxillofacial Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 2Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania 3Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 4Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania 5Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania Carney syndrome is a rare, autosomal dom- neoplastic colonic polyps; inant, multi-system disorder comprising 8 subcapsular cataracts; follic- well-characterized findings, only 2 of which ular thyroid carcinoma need be present for a definitive diagnosis. Benign neoplasms are frequent, but malig- nancies are thought to be uncommon. We INTRODUCTION have studied a family to clarify the diagno- sis and spectrum of clinical manifestations Carney syndrome (MIM number 160980) is a rare, of the syndrome and to develop guidelines multi-system, pre-neoplastic syndrome diagnosed for management. The proposita, a 34-year- when at least 2 of the following 8 findings are present: old woman had classic findings of Carney cardiac myxoma, cutaneous myxoma, myxoid mam- syndrome, invasive follicular carcinoma of mary fibroadenoma, spotty mucocutaneous pigmenta- the thyroid gland, Barrett metaplasia of the tion including lentigines and blue nevi, primary pig- esophagus, neoplastic colonic polyps, bipo- mented nodular adrenocortical disease (Cushing syn- lar affective disorder, and atypical mesen- drome), testicular tumor, growth-hormone–secreting chymal neoplasm of the uterine cervix dis- pituitary adenoma, and psammomatous melanotic tinct from the myxoid uterine leiomyoma schwannoma [Carney et al., 1985, 1986a,b; Cook et al., usually seen in this syndrome.
    [Show full text]
  • Incidence of Thyroid Neoplasm and Pancreatic Cancer In
    Redacted study protocol Incidence of Thyroid Neoplasm and Pancreatic Cancer in Type 2 Diabetes Mellitus Patients who Initiate Once Weekly Exenatide Compared with Other Antihyperglycemic Drugs Redacted protocol based on original protocol version 3 of August 14, 2013 LAY SUMMARY Many patients with diabetes mellitus, increased sugar levels, are treated with medicines. Different types of medicines are available. The present study is intended to monitor the occurrence of two types of cancer with weekly exenatide. Anonymised electronic health care records will be used to monitor the weekly exenatide users and compare them to patients using other types of medication. 1 BACKGROUND Diabetes mellitus is a major public health problem worldwide and especially in the United Kingdom (UK). According to Diabetes UK, approximately 2.8 million people in the UK had diabetes in 2010 [1]. Type 2 diabetes (T2DM) accounts for 90-95% of diagnosed cases of diabetes and is associated with older age, obesity, family history of diabetes, gestational diabetes, impaired glucose metabolism, physical inactivity. Diabetes is a leading cause of blindness, end-stage renal disease, non-traumatic lower limb amputation, and is a major risk factor for coronary artery disease and stroke [2]. Interventions that improve glycemic control reduce microvascular complications involving the eyes, kidneys and nerves, and may reduce macrovascular complications such as myocardial infarction [3]. Many of the traditional diabetes medications (such as sulfonylureas (SU), metformin, α-glucosidase inhibitors, thiazolidinediones (TZDs), and insulin) lower blood glucose, but they may also produce hypoglycemia, gastrointestinal symptoms, or weight gain. The American Diabetes Association recommends a hemoglobin A1C goal of less than 7%, but many diabetic patients are unable to achieve this goal by using oral drug combinations or diet and exercise.
    [Show full text]
  • Downloaded from Bioscientifica.Com at 09/26/2021 09:35:42AM Via Free Access
    25 2 Endocrine-Related S Redaelli et al. New treatments for MEN2 25:2 T53–T68 Cancer THEMATIC REVIEW Novel targeted therapeutics for MEN2 Sara Redaelli1, Ivan Plaza-Menacho2 and Luca Mologni1 1School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy 2Spanish National Cancer Research Center (CNIO), Madrid, Spain Correspondence should be addressed to L Mologni: [email protected] This paper is part of a thematic review section on 25 Years of RET and MEN2. The guest editors for this section were Lois Mulligan and Frank Weber Abstract The rearranged during transfection (RET) proto-oncogene was recognized as the Key Words multiple endocrine neoplasia type 2 (MEN2) causing gene in 1993. Since then, much f cell signaling effort has been put into a clear understanding of its oncogenic signaling, its biochemical f multiple endocrine function and ways to block its aberrant activation in MEN2 and related cancers. Several neoplasias small molecules have been designed, developed or redirected as RET inhibitors for the f oncogene treatment of MEN2 and sporadic MTC. However, current drugs are mostly active against f thyroid several other kinases, as they were not originally developed for RET. This limits efficacy and poses safety issues. Therefore, there is still much to do to improve targeted MEN2 treatments. New, more potent and selective molecules, or combinatorial strategies may lead to more effective therapies in the near future. Here, we review the rationale for RET targeting in MEN2, the use of currently available drugs and novel preclinical and clinical Endocrine-Related Cancer RET inhibitor candidates. (2018) 25, T53–T68 MEN2: introduction Mary (fictitious name) is a beautiful and joyful eighteen- features and mucosal neuromas of the lips and the year-old girl who enjoys her life.
    [Show full text]
  • Thyroid Cytology Bethesda Criteria and Molecular Analysis
    Thyroid Fine-Needle Aspiration Cytology & Molecular Testing Opinions & Criticisms Zubair W. Baloch, MD, PhD Professor of Pathology & Laboratory Medicine UPENN Medical Center, Philadelphia, PA Disclosure • Nothing to disclose Lets Start with Basics Objectives of Thyroid FNA • Recognize specific diagnostic entities • Provide meaningful, management oriented diagnosis • Utilization of ancillary techniques as needed The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) The Bethesda System for Reporting Thyroid Cytopathology: Implied Risk of Malignancy and Recommended Clinical Management Diagnostic Category Risk of Malignancy Usual Management (%) Non-diagnostic or Unsatisfactory Repeat FNA with ultrasound guidance Benign 0-3% Clinical follow-up Atypia of Undetermined Significance or ~ 5-15% Repeat FNA Follicular Lesion of Undetermined Significance (AUS/FLUS) Follicular Neoplasm or Suspicious for a 15-30% Surgical lobectomy Follicular Neoplasm (Specify if Hurthle type or Oncocytic) Suspicious for Malignancy 60-75% Near-total thyroidectomy or surgical lobectomy Malignant 97-99% Near-total thyroidectomy Easy Breezy Cytopathology Diagnosis Not Diagnostically Challenging Excellent Concordance Between Clinical Features, Ultrasound and Pathology Nodular Goiter Colloid: Generally abundant . Follicular cells Variable morphology Oncocytes, Macrophages Degeneration/regeneration: Calcification, stromal proliferation, mitoses Chronic Lymphocytic Thyroiditis Oncocytes Lymphocytes: In the background & infiltrating the cell groups Papillary Thyroid
    [Show full text]